Form 4: Arrowhead Director Sells Shares via Pre-Arranged Plan

Arrowhead Pharmaceuticals Director Victoria Vakiener sold 10,040 shares of common stock on December 19, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Victoria Vakiener, a Director at Arrowhead Pharmaceuticals, Inc. (ARWR), sold a total of 10,040 shares of common stock.
• The transactions occurred on December 19, 2025.
• The sales were executed under a Rule 10b5-1 trading plan, which allows insiders to sell shares at a predetermined time or price to avoid accusations of insider trading.
• The shares were sold in three separate transactions at weighted average prices of $66.63, $67.97, and $68.39.
• Specifically, 2,799 shares were sold at a weighted average price of $66.63 (ranging from $66.52 to $67.29).
• Another 5,281 shares were sold at a weighted average price of $67.97 (ranging from $67.36 to $68.20).
• A further 1,960 shares were sold at a weighted average price of $68.39 (ranging from $68.21 to $68.53).
• Following these transactions, Ms. Vakiener beneficially owns 35,723 shares of Arrowhead Pharmaceuticals common stock.
• The reported beneficial ownership includes previously reported shares underlying Restricted Stock Units, some of which are still subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sale of shares by a director is generally viewed neutrally to slightly negatively. However, the explicit mention of a Rule 10b5-1 trading plan indicates a pre-scheduled transaction for personal financial planning, which mitigates concerns about opportunistic selling based on non-public information, leading to a neutral sentiment.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than an opportunistic sale based on non-public information, which is a standard compliance practice.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived by some investors as a lack of confidence in the company's near-term stock price performance.

Risks

• While the 10b5-1 plan mitigates the immediate concern of insider trading, significant or repeated insider sales could be interpreted by the market as a signal of potential future challenges or a lack of strong upside conviction from management.

Future Outlook

No forward-looking statements or guidance were provided in this Form 4 filing, as it pertains solely to an insider's equity transaction.

Management Comments

• Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Industry Context

Insider transactions, particularly sales, are common in the biotechnology and pharmaceutical sectors, often related to personal financial planning, diversification, or exercise of stock options. The use of a 10b5-1 plan is a standard practice for executives and directors to manage their equity holdings in compliance with SEC regulations, providing a structured approach to avoid potential insider trading accusations.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a neutral event due to the 10b5-1 plan, or as a minor negative signal regarding future stock performance, depending on individual investment philosophy.

Key Dates

Recommendation

This Form 4 filing details a director's sale of shares under a pre-arranged 10b5-1 plan. While insider sales can sometimes be a negative signal, the 10b5-1 plan indicates a planned, non-discretionary transaction, reducing its immediate significance as a market indicator. This filing alone does not provide sufficient new information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate, pending further fundamental analysis of the company's operations and financials.

Keywords

Arrowhead Pharmaceuticals, ARWR, Insider Transaction, Form 4, Stock Sale, Director, 10b5-1 Plan, Equity Transaction, Pharmaceuticals, Biotechnology